Percutaneous Atrial Shunt Catheter System (PAS-C)
Symptomatic Heart Failure (with elevated left atrial pressure)
Pre-clinicalActive
Key Facts
Indication
Symptomatic Heart Failure (with elevated left atrial pressure)
Phase
Pre-clinical
Status
Active
Company
About InterShunt
InterShunt is a private, pre-revenue medical device company founded in 2020, targeting the large and growing heart failure market. Its core innovation is a mechanical, transcatheter system that excises tissue to form a left-to-right atrial shunt, offering a potential new treatment for patients with limited options. The company is led by a team with clinical and device development experience and is currently in the pre-clinical or early clinical development stage. Success hinges on demonstrating the safety and durable efficacy of its novel, implant-free approach in a competitive landscape.
View full company profile